Current Oncology | Free Full-Text | The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer | HTML
Efficacy of Palbociclib Combinations in Hormone Receptor–Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment - Clinical Breast Cancer
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer | NEJM
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Palbociclib Demonstrates Prolonged OS/PFS When Initiated in Metastatic Breast Cancer
Patient Case Lessons: Endocrine Management of Advanced Breast Cancer - Clinical Breast Cancer
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | SpringerLink
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer | NEJM
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | Semantic Scholar
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | Semantic Scholar
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice | Breast Cancer Research | Full Text
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial - The Lancet Oncology
ASCO 2021: Addition of Palbociclib to Fulvestrant Attains Overall Survival Benefit in Advanced Breast Cancer With Update of PALOMA-3 | PracticeUpdate
Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer - The Breast
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Why CDK 4/6 Inhibitors are Practice Changing in Advanced Breast Cancer - touchONCOLOGY
PALOMA-3 Exploratory Analysis Who Benefits Most From Palbociclib - The ASCO Post
No Clear Survival Benefit for Fulvestrant Versus Letrozole in Combination With Palbociclib for Endocrine-Sensitive Metastatic Breast Cancer
Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER) - European Journal of Cancer
Kaplan-Meier curves of progression-free survival among patients in... | Download Scientific Diagram
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Final analysis of progression-free survival in the PALOMA-3 study... | Download Scientific Diagram
